Eltrombopag Dose Adjustment During Reactive Secondary Thrombocytosis in patient with ITP
preprint
OA: closed
Abstract
Eltrombopag is relatively new drug used in Thrombocytopenia. Its dose should be adjusted based on platelets count. It should be stopped when platelets count reach 400,000/mm³. Here, we share our case report of stopping Eltrombopag based on platelets increment in secondary reactive thrombocytosis irrespective of Eltrombopag treatment.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00